Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibutamoren in Nonalcoholic Fatty Liver Disease
NCT05364684Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibutamoren in non-alcoholic fatty liver disease (NAFLD), sponsored by Massachusetts General Hospital. Started Aug 2022; status: completed.
02
Drugs
ibutamoren
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05364684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364684.